“We expect results from 4 additional orforglipron Phase III trials over the next 5 months, 3 trials in people with diabetes from our ACHIEVE program.”

In context

“es. There were no hepatic safety signals. We look forward to sharing detailed results from ATTAIN-1 also at the EASD Meeting in September and in a peer-reviewed publications. With today's readout, we've now seen results from 2 large Phase III clinical trials involving over 3,600 participants. And we're highly encouraged with what we've seen thus far. The data from these first 2 pivotal studies provide evidence that a once-daily oral GLP-1 can achieve efficacy and safety in line with injectable GLP-1s. Orforglipron has the potential to be a more convenient alternative to injectable treatments and to be utilized to support early disease intervention in the primary care setting. With these data in hand, we're now working to move quickly towards our first regulatory submissions yet this year. We expect results from 4 additional orforglipron Phase III trials over the next 5 months, 3 trials in people with diabetes from our ACHIEVE program. and 1 additional trial from the ATTAIN program in people with diabetes and obesity. ATTAIN-1 and ATTAIN-2 will support global submissions for chronic weight management, which we expect in Q4. In addition to the ongoing Phase III trials for orforglipron in diabetes, obesity, weight maintenance and obstructive sleep apnea, we initiated a new program for orforglipron this quarter, ATTAIN-Hypertension, focused on reducing systolic blood pressure at 36 weeks as the primary endpoint. This is the first study of orforglipron that includes patients with a baseline BMI as low as 25. We also announced plans to initiate a new Phase III trial in people with knee osteoarthritis pain in overweight or obesity starting later this year. Moving to pirtobrutinib. We announced positive results from the BRUIN”